NURS 5433 FNP II Final Exam
Review (2026/2027) (PDF) |
Family Nursing | UTA
ICS - answer-Inhaled corticosteroids used for asthma management.
Low ICS - answer-*Budesonide: 180-360 mcg/day (Pulmicort) and Fluticasone
propionate: 100-250 mcg/day (Flovent)
Beclomethasone: 80-160 mcg/day
Mometasone: 110 mcg/day
Medium ICS - answer-• Budesonide: 361-720 mcg/day (Pulmicort )
• Fluticasone propionate: 251-500 mcg/day (Flovent )
• Beclomethasone: 161-320 mcg/day
• Mometasone: 220-440 mcg/day
High ICS - answer-• Budesonide: >720 mcg/day (Pulmicort)
• Fluticasone propionate: >500 mcg/day (Flovent HFA)
• Beclomethasone: >320 mcg/day
• Mometasone: >440 mcg/day
SABA - answer-Short-acting beta agonists such as salbutamol (albuterol) and
terbutaline.
LAMA - answer-Long-acting muscarinic antagonists like tiotropium and
beclomethasone-formoterol glycopyrronium.
LABA - answer-Long-acting beta agonists such as salmeterol and formoterol.
ICS and LABA combo - answer-Combination medications like
beclomethasone/formoterol and budesonide/formoterol.
SAMA - answer-Short-acting muscarinic antagonists such as ipratropium bromide and
oxitropium bromide (combo with SABA).
Oral corticosteroids - answer-Prednisone, prednisolone, and methylprednisolone.
Anti-IgE - answer-Omalizumab, a medication used for asthma management.
, Leukotriene modifiers (LTRA) - answer-Medications such as montelukast, pranlukast,
and zileuton.
Sustained step-up treatment - answer-Increase treatment for at least 2-3 months if
symptoms persist despite controller treatment.
Common issues to consider before stepping up asthma tx - answer-Incorrect inhaler
technique, poor adherence, modifiable risk (smoking)
Short-term step-up treatment - answer-Temporary increase in treatment for 1-2 weeks
during exacerbations.
Day-to-day adjustment - answer-Using as-needed low dose ICS-formoterol for mild
asthma or ICS-formoteral as a maintenance and reliever therapy.
Stepping down treatment - answer-Reduce treatment once good asthma control has
been achieved for 3 months.
Reduce ICS dose by 20-50% at 2-3 month intervals.
Asthma action plan - answer-A written plan to manage asthma, including medication
adjustments.
GINA guidelines - answer-Global Initiative for Asthma guidelines for asthma
management.
Inhaled corticosteroids used for both RESUCE and MAINTENANCE.
GINA Step 3: SMART - answer-Single inhaler maintenance and reliever therapy using
LABA with ICS.
Pathophysiology of Asthma - answer-Involves inflammation, airway narrowing, excess
mucus production, and overreaction to triggers.
Presenting S&S of Asthma - answer-Symptoms include dyspnea, cough, chest
tightness, wheezing, tachypnea, and tachycardia.
Diagnostics for Asthma - answer-Includes CXR and spirometry with FEV1/FVC ratio of
<0.7 indicating airway obstruction.
COPD - answer-Chronic Obstructive Pulmonary Disease characterized by chronic
inflammation, airway obstruction, mucus overproduction, and emphysema.
Presenting S&S of COPD - answer-Symptoms that are slowly progressive, CHRONIC
COUGH, wheezing, chest tightness, frequent resp infection,
COPD risk factors - answer-History of tobacco smoking, environmental factors, genetic
predisposition, occupational hazards, and age are associated with COPD.
Review (2026/2027) (PDF) |
Family Nursing | UTA
ICS - answer-Inhaled corticosteroids used for asthma management.
Low ICS - answer-*Budesonide: 180-360 mcg/day (Pulmicort) and Fluticasone
propionate: 100-250 mcg/day (Flovent)
Beclomethasone: 80-160 mcg/day
Mometasone: 110 mcg/day
Medium ICS - answer-• Budesonide: 361-720 mcg/day (Pulmicort )
• Fluticasone propionate: 251-500 mcg/day (Flovent )
• Beclomethasone: 161-320 mcg/day
• Mometasone: 220-440 mcg/day
High ICS - answer-• Budesonide: >720 mcg/day (Pulmicort)
• Fluticasone propionate: >500 mcg/day (Flovent HFA)
• Beclomethasone: >320 mcg/day
• Mometasone: >440 mcg/day
SABA - answer-Short-acting beta agonists such as salbutamol (albuterol) and
terbutaline.
LAMA - answer-Long-acting muscarinic antagonists like tiotropium and
beclomethasone-formoterol glycopyrronium.
LABA - answer-Long-acting beta agonists such as salmeterol and formoterol.
ICS and LABA combo - answer-Combination medications like
beclomethasone/formoterol and budesonide/formoterol.
SAMA - answer-Short-acting muscarinic antagonists such as ipratropium bromide and
oxitropium bromide (combo with SABA).
Oral corticosteroids - answer-Prednisone, prednisolone, and methylprednisolone.
Anti-IgE - answer-Omalizumab, a medication used for asthma management.
, Leukotriene modifiers (LTRA) - answer-Medications such as montelukast, pranlukast,
and zileuton.
Sustained step-up treatment - answer-Increase treatment for at least 2-3 months if
symptoms persist despite controller treatment.
Common issues to consider before stepping up asthma tx - answer-Incorrect inhaler
technique, poor adherence, modifiable risk (smoking)
Short-term step-up treatment - answer-Temporary increase in treatment for 1-2 weeks
during exacerbations.
Day-to-day adjustment - answer-Using as-needed low dose ICS-formoterol for mild
asthma or ICS-formoteral as a maintenance and reliever therapy.
Stepping down treatment - answer-Reduce treatment once good asthma control has
been achieved for 3 months.
Reduce ICS dose by 20-50% at 2-3 month intervals.
Asthma action plan - answer-A written plan to manage asthma, including medication
adjustments.
GINA guidelines - answer-Global Initiative for Asthma guidelines for asthma
management.
Inhaled corticosteroids used for both RESUCE and MAINTENANCE.
GINA Step 3: SMART - answer-Single inhaler maintenance and reliever therapy using
LABA with ICS.
Pathophysiology of Asthma - answer-Involves inflammation, airway narrowing, excess
mucus production, and overreaction to triggers.
Presenting S&S of Asthma - answer-Symptoms include dyspnea, cough, chest
tightness, wheezing, tachypnea, and tachycardia.
Diagnostics for Asthma - answer-Includes CXR and spirometry with FEV1/FVC ratio of
<0.7 indicating airway obstruction.
COPD - answer-Chronic Obstructive Pulmonary Disease characterized by chronic
inflammation, airway obstruction, mucus overproduction, and emphysema.
Presenting S&S of COPD - answer-Symptoms that are slowly progressive, CHRONIC
COUGH, wheezing, chest tightness, frequent resp infection,
COPD risk factors - answer-History of tobacco smoking, environmental factors, genetic
predisposition, occupational hazards, and age are associated with COPD.
